In Silico Drug Discovery
Computational Strategies for Modern Drug Discovery
In silico drug discovery uses computational chemistry, molecular modeling, virtual screening, and predictive algorithms to identify, design, and prioritize promising compounds before synthesis and experimental testing. By evaluating large chemical libraries and modeling molecular interactions early, these approaches can reduce unnecessary laboratory work and help focus resources on candidates with the strongest potential.
WuXi Biology and Testing supports programs from hit finding through lead optimization by combining structure-based and ligand-based virtual screening, machine learning-enhanced DEL, ASMS/HTS and Direct-to-Biology (D2B) data analysis, molecular generation, docking, molecular dynamics, ADMET prediction, and binding-energy estimation. These computational capabilities are integrated with experimental screening and validation to support small molecule, peptide, and antibody discovery with greater speed and confidence.
Hit Finding: Computational Virtual Screening
Finding high-quality hits begins with efficiently exploring vast chemical space before compounds are synthesized or experimentally screened. WuXi Biology and Testing combines structure- and ligand-based virtual screening with machine learning-enhanced analysis to prioritize candidates with the highest likelihood of success for downstream validation.
Our virtual screening capabilities include:
- Structure-based virtual screening: Molecular docking against experimentally determined cocrystal structures or AlphaFold2-predicted protein structures, screening libraries of up to 14 million in-stock compounds.
- Ligand-based virtual screening: 3D shape, pharmacophore, and 2D fingerprint screening using WuXi Biology's proprietary GalaXi library (20 million compounds) and commercial libraries exceeding 10 billion compounds.
- Machine learning-enhanced virtual screening: Integration of DNA-encoded library (DEL) and affinity selection mass spectrometry (ASMS) or HTS datasets with machine learning (DEL+ML, ASMS/HTS+ML, DEL+ASMS/HTS+ML) to improve hit optimizability and reduce cost.
Hit-to-Lead: Computational Molecule Design and Optimization
Once promising hits have been identified, computational modeling guides the optimization of chemical series before synthesis, helping medicinal chemistry teams make more informed design decisions while reducing experimental cycles.
Our hit-to-lead capabilities include:
- Molecule generation: De novo, scaffold-based, and fragment-based approaches to expand and optimize chemical series.
- Structure-guided optimization: Molecular docking and molecular dynamics simulations to evaluate binding modes and complex stability.
- Binding free-energy estimation: MM/GB(PB)SA calculations and free energy perturbation (FEP) to prioritize binding affinity and support structure-activity relationship (SAR)-driven optimization.
- DEL-guided SAR analysis: Structure-activity relationship analysis informed by DNA-encoded library screening data to prioritize promising analogs.
Lead Optimization: Predictive ADMET and Binding Analysis
As lead compounds mature, computational prediction helps identify molecules with the greatest potential to progress into experimental development by evaluating developability alongside biological activity.
Our lead optimization capabilities include:
- Predictive ADMET modeling: Early assessment of absorption, distribution, metabolism, excretion, and toxicity to identify potential liabilities before synthesis.
These computational tools complement medicinal chemistry and experimental testing, enabling more informed compound prioritization throughout lead optimization.
In Silico Drug Discovery Across Therapeutic Modalities
Computational drug discovery supports the discovery and optimization of diverse therapeutic modalities by helping researchers prioritize candidates, refine molecular design, and guide experimental decision-making throughout the drug discovery process.
These capabilities support:
- Small molecules: Virtual screening, de novo molecular design, molecular docking, molecular dynamics simulations, predictive ADMET modeling, and binding affinity estimation to accelerate hit identification and lead optimization.
- Peptides: Conformation modeling, sequence design, cyclization and lipidation modelling, molecular dynamics simulations, and structure-guided hit-to-lead optimization to improve candidate binding affinity and properties.
- Antibody: In silico affinity maturation, humanization, and structure modelling to support optimization. By integrating computational drug discovery with DNA-encoded library (DEL) screening, affinity selection mass spectrometry (ASMS), HTS, medicinal chemistry, biochemical assays, and cellular pharmacology, we provide a seamless transition from computational prediction to experimental validation across the drug discovery workflow.
Explore Solutions for Your Program
Explore solutions by development phase, drug modality, therapeutic area, or integrated discovery needs.
You May Also Be Interested In
Get a Quote
Ready to plan your next study? Share your program needs with our team for a tailored estimate.
Frequently Asked Questions
In silico drug discovery uses computational methods, including molecule generation, virtual screening, molecular docking, molecular dynamics, machine learning modelling and predictive ADMET analysis to identify, design, and optimize drug candidates before experimental testing. These approaches help researchers prioritize promising compounds, reduce unnecessary synthesis, and accelerate hit finding and lead optimization.
Virtual screening is a computational approach that evaluates large libraries of compounds to identify molecules most likely to bind a therapeutic target. WuXi Biology and Testing supports both structure-based virtual screening using molecular docking and ligand-based virtual screening using 3D shape, pharmacophore, and 2D fingerprint methods, with access to libraries containing billions of commercially available and proprietary compounds.
Structure-based virtual screening predicts compound binding using experimentally determined or AlphaFold2-predicted protein structures. Ligand-based virtual screening identifies new compounds based on their similarity to known active molecules using shape, pharmacophore, or chemical fingerprint analyses. Depending on the available biological information, these complementary approaches can be used independently or together to improve hit identification.
Following hit identification, computational methods help refine and prioritize compounds before synthesis. WuXi Biology and Testing supports de novo, scaffold-based, and fragment-based molecule generation, molecular docking, molecular dynamics simulations, MM/GB(PB)SA calculations, free energy perturbation (FEP) and DEL-guided structure-activity relationship (SAR) analysis to guide efficient hit-to-lead optimization.
Computational lead optimization combines predictive ADMET modeling with binding free-energy calculations (MM/GB(PB)SA or FEP) to evaluate pharmacokinetic properties, identify potential liabilities, estimate binding affinity, and prioritize compounds with the greatest likelihood of success before experimental testing.
Our computational platform supports small molecule, peptide and antibody discovery throughout hit finding, hit-to-lead and lead optimization. Predictive ADMET modeling and binding free-energy estimation are currently focused on small molecule hit-to-lead/lead optimization. For antibody discovery, we support structure modelling, in silico affinity maturation and humanization.
Project timelines vary depending on the computational strategy and virtual library selected. Structure-based and ligand-based virtual screening typically requires 2-3 weeks. Integrated workflows combining DEL or ASMS/HTS screening with computational analysis require additional experimental time, with computational timelines ranging from 1-3 weeks and overall timelines ranging from approximately 6–9weeks depending on the approach.